AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11052579 — intervention group
Group type: EXPERIMENTAL
Intervention: Planned caesarean section
Number of subjects: 2088
Study 11052579 — intervention group
Group type: COMPARATOR
Intervention: Planned vaginal birth
Number of subjects: 2088
Study 8782129 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D 50,000 units/week and calcium 1,000 mg/day
Number of subjects: 62
Study 8782129 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 1419761 — intervention group
Group type: EXPERIMENTAL
Intervention: terbinafine 1% cream applied for 1 day
Number of subjects: 20
Study 1419761 — intervention group
Group type: EXPERIMENTAL
Intervention: terbinafine 1% cream applied for 3, 5, or 7 consecutive days
Number of subjects: 20
Study 1419761 — intervention group
Group type: EXPERIMENTAL
Intervention: terbinafine 1% cream applied for 7 days
Number of subjects: 20
Study 6371875 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone (100-200 mg, nocte)
Number of subjects: 125
Study 6371875 — intervention group
Group type: COMPARATOR
Intervention: Mianserin (60-120 mg, nocte)
Number of subjects: 125
Study 6371875 — intervention group
Group type: COMPARATOR
Intervention: Mianserin
Number of subjects: 125
Study 6371875 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 125
Study 31380684 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive mood intervention (15-min video package)
Number of subjects: 103
Study 31380684 — intervention group
Group type: COMPARATOR
Intervention: Neutral control video
Number of subjects: 103
Study 31380684 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive mood intervention
Number of subjects: 103
Study 31380684 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 103
Study 29983409 — intervention group
Group type: EXPERIMENTAL
Intervention: CCH injection
Number of subjects: 258
Study 29983409 — intervention group
Group type: COMPARATOR
Intervention: ADH injection
Number of subjects: 258
Study 29983409 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 258
Study 27178983 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line chemotherapy for advanced NSCLC
Number of subjects: 22709
Study 25151550 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy with tone enhancement (Group B)
Number of subjects: 80
Study 25151550 — intervention group
Group type: COMPARATOR
Intervention: White light colonoscopy (Group A)
Number of subjects: 80
Study 22429765 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined strengthening, stretching and functional training program, 12 weeks, twice a week, 40-60 minutes each session.
Number of subjects: 0
Study 22429765 — intervention group
Group type: COMPARATOR
Intervention: Usual-care (control group), details not specified.
Number of subjects: 0
Study 20178889 — intervention group
Group type: EXPERIMENTAL
Intervention: Fascia iliaca block (FIB) (n = 51)
Number of subjects: 98
Study 20178889 — intervention group
Group type: COMPARATOR
Intervention: Femoral nerve block (FNB) (n = 47)
Number of subjects: 98
Study 17285514 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 60
Study 17285514 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 60
Study 16253099 — intervention group
Group type: EXPERIMENTAL
Intervention: CPF + CT
Number of subjects: 3
Study 16253099 — intervention group
Group type: EXPERIMENTAL
Intervention: DP + CT
Number of subjects: 3
Study 16253099 — intervention group
Group type: EXPERIMENTAL
Intervention: TUN-LAT + CT
Number of subjects: 3
Study 12032789 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal saline solution
Number of subjects: 61
Study 12032789 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactated Ringer's solution
Number of subjects: 61
Study 12032789 — intervention group
Group type: COMPARATOR
Intervention: Control (clear amniotic fluid)
Number of subjects: 61
Study 11105476 — intervention group
Group type: EXPERIMENTAL
Intervention: Confusing questions (negatives, double negatives, leading, multiple questions, complex syntax, and complex vocabulary)
Number of subjects: 0
Study 11105476 — intervention group
Group type: COMPARATOR
Intervention: Simply phrased equivalents
Number of subjects: 0
Study 9187187 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive assist-control ventilation (ACV)
Number of subjects: 15
Study 9187187 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure support ventilation (PSV)
Number of subjects: 15
Study 9187187 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous breathing (SB)
Number of subjects: 15
Study 1493431 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg
Number of subjects: 20
Study 1493431 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 3541052 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone 100 mg daily
Number of subjects: 9
Study 3541052 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 30827735 — intervention group
Group type: EXPERIMENTAL
Intervention: Active clinicians in middle-class communities after first interaction
Number of subjects: 30
Study 30827735 — intervention group
Group type: EXPERIMENTAL
Intervention: Active clinicians in middle-class communities after second interaction
Number of subjects: 30
Study 30827735 — intervention group
Group type: COMPARATOR
Intervention: Control clinicians in middle-class communities
Number of subjects: 30
Study 29710136 — intervention group
Group type: EXPERIMENTAL
Intervention: Physicians using an examination room computer
Number of subjects: 0
Study 29710136 — intervention group
Group type: COMPARATOR
Intervention: Physicians not using an examination room computer
Number of subjects: 0
Study 27769210 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel plus gemcitabine (nab-P + Gem)
Number of subjects: 0
Study 27769210 — intervention group
Group type: COMPARATOR
Intervention: gemcitabine (Gem)
Number of subjects: 0
Study 24444353 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐IFN therapy
Number of subjects: 119
Study 22209798 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma-focused cognitive-behavioral therapy (TF-CBT)
Number of subjects: 26
Study 22209798 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 26
Study 20045278 — intervention group
Group type: EXPERIMENTAL
Intervention: Early invasive strategy
Number of subjects: 1200
Study 20045278 — intervention group
Group type: COMPARATOR
Intervention: Selective invasive strategy
Number of subjects: 1200
Study 17564278 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP treatment for at least two years
Number of subjects: 35
Study 17564278 — intervention group
Group type: COMPARATOR
Intervention: Untreated patients (refused CPAP therapy)
Number of subjects: 35
Study 15982224 — intervention group
Group type: EXPERIMENTAL
Intervention: Nickel
Number of subjects: 0
Study 15982224 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11874388 — intervention group
Group type: EXPERIMENTAL
Intervention: cetirizine 10 mg
Number of subjects: 36
Study 11874388 — intervention group
Group type: EXPERIMENTAL
Intervention: mizolastine 10 mg
Number of subjects: 36
Study 11874388 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 36
Study 10519674 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose, insulin and potassium
Number of subjects: 30
Study 10519674 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 30
Study 7805253 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary PTCA
Number of subjects: 8496
Study 7805253 — intervention group
Group type: COMPARATOR
Intervention: Thrombolysis and PTCA
Number of subjects: 8496
Study 7805253 — intervention group
Group type: COMPARATOR
Intervention: Thrombolysis and PTCA (routine strategy)
Number of subjects: 8496
Study 2127257 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral flurbiprofen (150 mg)
Number of subjects: 8
Study 2127257 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 8
Study 30203677 — intervention group
Group type: EXPERIMENTAL
Intervention: Home‐based Individually tailored Physical activity Print (HIPP) intervention
Number of subjects: 84
Study 30203677 — intervention group
Group type: COMPARATOR
Intervention: Wellness contact control
Number of subjects: 84
Study 31547377 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (3200 IU per day for five weeks before surgery)
Number of subjects: 33
Study 31547377 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vegetable oil during the same time)
Number of subjects: 33
Study 31547377 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation
Number of subjects: 33
Study 31547377 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation and supplementation
Number of subjects: 33
Study 27443171 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsinoid ingestion
Number of subjects: 0
Study 27443171 — intervention group
Group type: COMPARATOR
Intervention: Placebo ingestion
Number of subjects: 0
Study 25160845 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced calorie weight loss diet (n = 118)
Number of subjects: 439
Study 25160845 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate‐ to vigorous‐intensity aerobic exercise (n = 117)
Number of subjects: 439
Study 25160845 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of diet and exercise (n = 117)
Number of subjects: 439
Study 25160845 — intervention group
Group type: COMPARATOR
Intervention: Control (n = 87)
Number of subjects: 439
Study 23915267 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial intervention (organizational and training for professionals)
Number of subjects: 15
Study 23915267 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 15
Study 21839884 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyspepsia (functional or organic)
Number of subjects: 850
Study 21839884 — intervention group
Group type: COMPARATOR
Intervention: Functional dyspepsia
Number of subjects: 850
Study 21839884 — intervention group
Group type: COMPARATOR
Intervention: Organic dyspepsia
Number of subjects: 850
Study 19131655 — intervention group
Group type: EXPERIMENTAL
Intervention: Prearrival communication via fax and telephone call to patient/surrogate
Number of subjects: 100
Study 19131655 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prearrival communication)
Number of subjects: 100
Study 19131655 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful prearrival communications
Number of subjects: 100
Study 19131655 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (ranitidine infusion during flight)
Number of subjects: 100
Study 19131655 — intervention group
Group type: COMPARATOR
Intervention: Recruitment initiation on arrival
Number of subjects: 100
Study 17380181 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 15025614 — intervention group
Group type: EXPERIMENTAL
Intervention: 90-min application of Lidocaine/Prilocaine cream followed by a 30-min interval before cannulation (Group B)
Number of subjects: 60
Study 15025614 — intervention group
Group type: COMPARATOR
Intervention: 60-min application of Lidocaine/Prilocaine cream followed by immediate cannulation (Group A)
Number of subjects: 60
Study 11561265 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 18
Study 11561265 — intervention group
Group type: COMPARATOR
Intervention: Intravenous morphine patient-controlled analgesia (PCA)
Number of subjects: 18
Study 9749274 — intervention group
Group type: EXPERIMENTAL
Intervention: rtPA (recombinant tissue plasminogen activator) administered at the pick-up point
Number of subjects: 1200
Study 9749274 — intervention group
Group type: COMPARATOR
Intervention: Primary angioplasty performed in hospital
Number of subjects: 1200
Study 7848592 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (100, 200, and 300 micrograms subcutaneously every 8 hours)
Number of subjects: 20
Study 7848592 — intervention group
Group type: COMPARATOR
Intervention: High doses of loperamide and diphenoxylate orally plus placebo subcutaneously for 10 days
Number of subjects: 20
Study 3228575 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet B (MOTRIN Tablet) 400 mg
Number of subjects: 12
Study 3228575 — intervention group
Group type: COMPARATOR
Intervention: Tablet A (generic ibuprofen tablet) 400 mg
Number of subjects: 12
Study 3228575 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Tablet A and Tablet B
Number of subjects: 12
Study 5448798 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron therapy
Number of subjects: 47
Study 5448798 — intervention group
Group type: COMPARATOR
Intervention: Control (baseline assessment before treatment)
Number of subjects: 47
Study 29121401 — intervention group
Group type: EXPERIMENTAL
Intervention: MP29-02 (azelastine hydrochloride and fluticasone propionate)
Number of subjects: 28
Study 29121401 — intervention group
Group type: EXPERIMENTAL
Intervention: AZE + FP
Number of subjects: 28
Study 29231508 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture anesthesia (needles retained for 10 min after tooth extraction)
Number of subjects: 60
Study 29231508 — intervention group
Group type: COMPARATOR
Intervention: Drug local block anesthesia (compound articaine hydrochloride injection)
Number of subjects: 60
Study 29231508 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Acupuncture and Drug)
Number of subjects: 60
Study 26629707 — intervention group
Group type: EXPERIMENTAL
Intervention: Training program based on letter-speech sound associations, 34 individual sessions of 45 minutes over five months.
Number of subjects: 44
Study 26629707 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 44
Study 23969184 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide implant (84 mg)
Number of subjects: 163
Study 23969184 — intervention group
Group type: COMPARATOR
Intervention: Octreotide LAR (10-40 mg)
Number of subjects: 163
Study 23969184 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide implant
Number of subjects: 163
Study 23969184 — intervention group
Group type: COMPARATOR
Intervention: Octreotide LAR
Number of subjects: 163
Study 20436711 — intervention group
Group type: EXPERIMENTAL
Intervention: Clevudine (30 mg once daily)
Number of subjects: 116
Study 20436711 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine (100 mg once daily)
Number of subjects: 116
Study 18486741 — intervention group
Group type: EXPERIMENTAL
Intervention: ASC plus chemotherapy (MVP and vinorelbine combined)
Number of subjects: 409
Study 18486741 — intervention group
Group type: EXPERIMENTAL
Intervention: ASC plus vinorelbine
Number of subjects: 409
Study 18486741 — intervention group
Group type: EXPERIMENTAL
Intervention: ASC plus MVP
Number of subjects: 409
Study 18486741 — intervention group
Group type: COMPARATOR
Intervention: ASC alone
Number of subjects: 409
Study 16813181 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with microorganism pharmaceutical preparations (Group A)
Number of subjects: 95
Study 16813181 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of medicine for loosening the bowel to relieve constipation plus microorganism pharmaceutical preparations (Group B)
Number of subjects: 95
Study 16813181 — intervention group
Group type: COMPARATOR
Intervention: Simple acupuncture (Group C)
Number of subjects: 95
Study 15023641 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% Na + 0.00% CDG sausage
Number of subjects: 65
Study 15023641 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% Na + 0.10% CDG sausage
Number of subjects: 65
Study 15023641 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% Na + 0.40% CDG sausage
Number of subjects: 65
Study 15023641 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.69% Na + 0.00% CDG sausage
Number of subjects: 65
Study 11139979 — intervention group
Group type: EXPERIMENTAL
Intervention: Tilt table testing with noninvasive brain and skeletal muscle oximetry in patients with syncope.
Number of subjects: 24
Study 11139979 — intervention group
Group type: COMPARATOR
Intervention: Tilt table testing in healthy volunteers.
Number of subjects: 24
Study 11139979 — intervention group
Group type: EXPERIMENTAL
Intervention: Tilt table testing with simultaneous assessment of brain and skeletal muscle oxygenation.
Number of subjects: 24
Study 8975684 — intervention group
Group type: EXPERIMENTAL
Intervention: Edge-assignment in contour matching task
Number of subjects: 8
Study 8975684 — intervention group
Group type: EXPERIMENTAL
Intervention: Deliberate attention to one region of an ambiguous figure-ground display
Number of subjects: 8
Study 1291185 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol gum
Number of subjects: 28
Study 1291185 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorbitol gum
Number of subjects: 28
Study 1291185 — intervention group
Group type: COMPARATOR
Intervention: No chewing phase (Control)
Number of subjects: 28
Study 6379505 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 160 mg/d
Number of subjects: 0
Study 6379505 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 320 mg/d
Number of subjects: 0
Study 6379505 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6379505 — intervention group
Group type: COMPARATOR
Intervention: Propranolol 80 mg/d
Number of subjects: 0
Study 29431228 — intervention group
Group type: EXPERIMENTAL
Intervention: MAS063DP lotion
Number of subjects: 16
Study 29431228 — intervention group
Group type: COMPARATOR
Intervention: 0.02% triamcinolone acetonide lotion
Number of subjects: 16
Study 26607831 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium butyrate enemas (30ml of sodium butyrate 600mmol/L, b.i.d. for 30 days)
Number of subjects: 20
Study 26607831 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo, b.i.d. for 30 days)
Number of subjects: 20
Study 26607831 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium butyrate enemas
Number of subjects: 20
Study 23659682 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupation-focused family intervention
Number of subjects: 30
Study 22370739 — intervention group
Group type: EXPERIMENTAL
Intervention: Capadenoson 10 mg
Number of subjects: 62
Study 22370739 — intervention group
Group type: EXPERIMENTAL
Intervention: Capadenoson 20 mg
Number of subjects: 62
Study 22370739 — intervention group
Group type: EXPERIMENTAL
Intervention: Capadenoson (various doses)
Number of subjects: 62
Study 22370739 — intervention group
Group type: EXPERIMENTAL
Intervention: Capadenoson
Number of subjects: 62
Study 22370739 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 19640572 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose Change
Number of subjects: 160
Study 19640572 — intervention group
Group type: COMPARATOR
Intervention: No change
Number of subjects: 160
Study 17851565 — intervention group
Group type: EXPERIMENTAL
Intervention: Baicalin (50 mg tablets, three times daily for 14 days)
Number of subjects: 18
Study 15681300 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (10 mg twice daily)
Number of subjects: 11
Study 15681300 — intervention group
Group type: COMPARATOR
Intervention: Losartan (50 mg twice daily)
Number of subjects: 11
Study 15681300 — intervention group
Group type: EXPERIMENTAL
Intervention: Bradykinin (30 to 300 pmol/min)
Number of subjects: 11
Study 15681300 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine (60 to 540 pmol/min)
Number of subjects: 11
Study 15681300 — intervention group
Group type: EXPERIMENTAL
Intervention: Lys-des-Arg9-bradykinin (1 to 10 nmol/min)
Number of subjects: 11
Study 15681300 — intervention group
Group type: EXPERIMENTAL
Intervention: Lys-[Leu8]-des-Arg9-bradykinin (1 to 10 nmol/min)
Number of subjects: 11
Study 12832973 — intervention group
Group type: EXPERIMENTAL
Intervention: Hilar dissection (G1)
Number of subjects: 80
Study 12832973 — intervention group
Group type: COMPARATOR
Intervention: 'Glissonean' approach and stapling of the pedicle (G2)
Number of subjects: 80
Study 12832973 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (G1 and G2)
Number of subjects: 80
Study 10511131 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin (1 mg o.d. for 3 days, followed by 2 mg o.d. for 7 days)
Number of subjects: 28
Study 10511131 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 8895264 — intervention group
Group type: EXPERIMENTAL
Intervention: HBOC-201 (3 mL/kg)
Number of subjects: 13
Study 8895264 — intervention group
Group type: COMPARATOR
Intervention: HES (6%)
Number of subjects: 13
Study 2049684 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine 20 mg once daily
Number of subjects: 78
Study 2049684 — intervention group
Group type: COMPARATOR
Intervention: Nitrendipine 10 mg bid
Number of subjects: 78
Study 6509877 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination tablet containing triprolidine hydrochloride and pseudoephedrine hydrochloride
Number of subjects: 19
Study 6509877 — intervention group
Group type: COMPARATOR
Intervention: Syrup containing triprolidine hydrochloride and pseudoephedrine hydrochloride
Number of subjects: 19
Study 6509877 — intervention group
Group type: COMPARATOR
Intervention: Single-ingredient tablet of pseudoephedrine
Number of subjects: 19
Study 6509877 — intervention group
Group type: COMPARATOR
Intervention: Single-ingredient tablet of triprolidine
Number of subjects: 19
Study 31011266 — intervention group
Group type: EXPERIMENTAL
Intervention: Green Gloo adhesive
Number of subjects: 18
Study 31011266 — intervention group
Group type: COMPARATOR
Intervention: Transbond XT adhesive
Number of subjects: 18
Study 28918732 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture alone (177 patients)
Number of subjects: 528
Study 28918732 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture plus pharmacotherapy (178 patients)
Number of subjects: 528
Study 28918732 — intervention group
Group type: COMPARATOR
Intervention: Pharmacotherapy alone (173 patients)
Number of subjects: 528
Study 25942472 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced Glycerin Vaginal Formulation (RGVF) gel - 7 daily doses
Number of subjects: 0
Study 25942472 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal Specific Formulation (RF) gel - 7 daily doses
Number of subjects: 0
Study 25942472 — intervention group
Group type: COMPARATOR
Intervention: Placebo - 6 daily doses followed by 1 dose of Vaginal Formulation (VF) gel
Number of subjects: 0
Study 23651713 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan (ARB)
Number of subjects: 82
Study 23651713 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82